Computational and Structural Biotechnology Journal (Jan 2021)

De novo mutations in folate-related genes associated with common developmental disorders

  • Tengfei Luo,
  • Kuokuo Li,
  • Zhengbao Ling,
  • Guihu Zhao,
  • Bin Li,
  • Zheng Wang,
  • Xiaomeng Wang,
  • Ying Han,
  • Lu Xia,
  • Yi Zhang,
  • Qiao Zhou,
  • Zhenghuan Fang,
  • Yijing Wang,
  • Qian Chen,
  • Xun Zhou,
  • Hongxu Pan,
  • Yuwen Zhao,
  • Yige Wang,
  • Lijie Dong,
  • Yuanfeng Huang,
  • Zhengmao Hu,
  • Qian Pan,
  • Kun Xia,
  • Jinchen Li

Journal volume & issue
Vol. 19
pp. 1414 – 1422

Abstract

Read online

Folate deficiency is an environmental risk factor for several developmental disorders. De novo mutations (DNMs) also play important etiological roles in various developmental disorders. However, it remains unclear whether DNMs in folate-related genes (FRGs) contribute to developmental disorders. We obtained a list of 1,821 FRGs from folate metabolism pathways and the Comparative Toxicogenomics Database, along with data concerning DNMs in 15,404 cases and 3,391 controls from the Gene4Denovo database. We used a TADA-Denovo model to prioritize candidate disease-associated FRGs, and characterized these genes in terms of genic intolerance, functional networks, and expression patterns. Compared with the controls, FRGs were significantly enriched in likely damaging DNMs (ldDNMs) in patients with developmental disorders (1.54 ≤ odds ratio ≤ 3.39, Padj ≤ 0.0075). Furthermore, FRGs with ldDNMs rather than with likely non-damaging DNMs (lndDNMs) overlapped significantly among the five developmental disorders included in the datasets. The TADA-Denovo model prioritized 96 candidate disease-associated FRGs, which were intolerant to genetic variants. Their functional networks mainly involved pathways associated with chromatin modification, organ development, and signal transduction pathways. DNMT3A, KMT2B, KMT2C, and YY1 emerged as hub FRGs from the protein–protein interaction network. These candidate disease-associated FRGs are preferentially expressed in the excitatory neurones during embryonic development, and in the cortex, cerebellum, striatum, and amygdala during foetal development. Overall, these findings show that DNMs in FRGs are associated with the risk of developmental disorders. Further research on these DNMs may facilitate the discovery of developmental disorder biomarkers and therapeutic targets, enabling detailed, personalized, and precise folate treatment plan.

Keywords